Biotechnology

ProRx Pharma touts a major expansion to meet drug demand, but recent FDA warnings and massive recalls raise serious questions about its quality and safety.

AI promises to transform drug discovery, but billions in investment are at risk. A new report reveals why the real bottleneck isn't tech, but data itself.

With a new CEO known for billion-dollar deals, Modulari-T Biosciences is poised to commercialize its next-gen in vivo cell therapy platform.

The medtech giant posts Q1 growth and secures critical EU approvals for new devices, navigating post-pandemic shifts and geopolitical headwinds with strong cash flow.

Biotech firm BiomEdit has secured patents for a novel biologic that uses engineered probiotics to fight a costly poultry disease, paving the way for antibiotic-free farming.

A new partnership aims to develop a diagnostic test for a hidden cancer biomarker, potentially unlocking a targeted therapy for patients with grim prognoses.

A UK biotech's Rincell-1 therapy enters human trials, aiming to regenerate auditory nerves and restore hearing where current technology falls short.

With a fresh $60 million IPO, JATT II is targeting the next wave of healthcare innovators using AI and machine learning to revolutionize drug discovery.

With a $719M war chest from its blockbuster IPO, Kailera Therapeutics is poised to challenge the dominance of Lilly and Novo in the lucrative obesity market.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

ATCC and the Broad Institute unveil engineered lung cancer cells to decode drug resistance, offering new hope for patients and fueling AI-driven discovery.

Atsena Therapeutics gets the green light for the final trial phase of a promising gene therapy, offering the first real hope for patients with X-linked retinoschisis.

Tenvie Therapeutics begins human trials for TNV108, a drug that targets the root cause of nerve decay, offering a potential disease-modifying breakthrough.

PeptiDream and Asahi Kasei's novel drug candidate, AK1940, begins Phase 1 trials, aiming for a safer, more targeted approach to treating autoimmune diseases.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

A breakthrough drug for pediatric Hunter syndrome, AVLAYAH™, is now accessible via home infusion through an exclusive Orsini and Denali partnership.

A landmark conference merges top organizations to accelerate research on retinal diseases, from gene editing to AI, offering new hope for millions worldwide.